GlassScriptPhysician profile
Ian Crespo Orta
NPI 1538746318
$2,322.41
in general payments reported to CMS, 2019-2025
25 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.14 · 2024: $794 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.43 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $267.26 | 2024-2025 | Blincyto, Blincyto, Kyprolis |
| Adaptive Biotechnologies Corporation | $265.90 | 2024-2025 | Clonoseq |
| Tempus Ai, INC | $260.81 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $177.31 | 2024-2025 | |
| Sobi, INC | $155.84 | 2023-2025 | |
| Genzyme Corporation | $151.91 | 2025 | |
| Servier Pharmaceuticals LLC | $127.59 | 2025 | |
| Janssen Pharmaceuticals, INC | $119.67 | 2024-2025 | Erleada, Rybrevant, Akeega |
| Genmab U.S., INC. | $109.86 | 2024 | Epkinly |
| Seagen INC. | $99.99 | 2025 | |
| Pbg Puerto Rico LLC | $65.23 | 2025 | |
| Exelixis INC. | $56.14 | 2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $55.21 | 2025 | Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $46.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $45.60 | 2025 | Calquence |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $43.09 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $42.87 | 2025 | Jemperli, Zejula |
| Pfizer INC. | $42.28 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.33 | 2024 | Advate |
| Regeneron Healthcare Solutions, INC. | $31.25 | 2025 | Libtayo |
| Genentech USA, INC. | $26.96 | 2025 | Phesgo |
| Eisai INC. | $26.60 | 2025 | |
| Incyte Corporation | $25.00 | 2025 | Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $23.45 | 2025 | Reblozyl |
| Biogen, INC. | $22.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Crespo Orta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.